this presentation has been developed by boehringer ingelheim ltd. and eli lilly company ltd....
TRANSCRIPT
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
Alliance Meeting Portfolio
Type 2 diabetes care and the changing NHS
Boehringer Ingelheim and Lilly provided funding for this sponsored session, including speaker honoraria and agency support. Boehringer Ingelheim and Lilly have reviewed the presentation for medical accuracy and compliance with
applicable laws and regulations.
Trajenta ® ▼ (linagliptin) and Jentadueto ® ▼ (linagliptin and metformin) prescribing information can be found at the end of this presentation
Adverse events should be reported. Reporting forms and information can be found at www. mhra.gov.uk/yellowcard.Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
Overview and objectives
• This module contains an overview of the recent changes in the structure of the NHS and the practical implications for T2D care
• The main learning objectives are to:– Understand the evolution of the NHS prior to the restructure in April 2013
and the challenges the healthcare service is facing– Review the new structure of the NHS, focusing on the role of CCGs in
treatment purchasing and planning, and control of funding– Highlight the need for organised, co-ordinated and structured models of
integrated T2D care delivery– Understand how the NHS Outcomes Framework and the CCGOIS are
used to monitor standards of care on patients with T2D– Review the QOF framework for diabetes and the potential impact of the
NHS changes on diabetes care
NHS: National Health Service; CCGs: Clinical Commissioning Groups; T2D: type 2 diabetes; CCGOIS: Clinical Commissioning Group Outcomes Indicator Set; QOF: Quality and Outcomes Framework.
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
Evolution of the NHS: the drive for change
1. Adapted from Gorsky, M. Social History of Medicine Vol. 21, No. 3 pp. 437–460. 2. The NHS at 60. Available at: http://www.nhs.uk/NHSEngland/thenhs/nhshistory/Pages/NHShistory1948.aspx. 3. NHS reforms timeline. The Nuffield Trust. Available at http://nhstimeline.nuffieldtrust.org.uk/. 4. National Service Frameworks.2002. Available at http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4050864.pdf. 5. National Institute for Health and Clinical Excellence. Available at: http://www.nice.org.uk.6. Commissioning Outcomes Framework: Engagement Document. NHS Commissioning Board. 2011. Available at http://www.commissioningboard.nhs.uk/files/2011/11/COF-final1.pdf . All
online resources accessed October 2013.
1948 1960s
‘The Hospital plan (1962)’
District hospitals2
Concept of primary care1
1970s
Regional Health
Authorities1
1980s 1990
‘Working for patients (1989)’3
‘National Health Service and
Community Care Act (1990)’ 2
NHS trusts1
1997
‘The New NHS’ 1
2000 2005 2010 2015
NSFs4
PCTs and Foundation
Trusts2
QOFs5
New NHS structure?
Clinical governance
NICE5
COFs6
1
NHS: National Health Service; NICE: National Institute for Health and Clinical Excellence; NSFs: National Service Frameworks; PCTs: Primary Care Trusts; QOFs: Quality and Outcomes Framework; COFs: Commissioning Outcomes Framework.
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
NHS structure: pre-April 2013
Department of Health
10 Strategic Health Authorities
152 Primary Care Trusts
Primary care services:
GPs, dentistry, community pharmacy,
opticians etc.
Community health services
e.g. district nursing, health
visitors
Acute hospital trusts
NHS foundation
trusts
Mental health trusts
Ambulance trusts
Commercial providers and
voluntary organisations
Private providers
Care quality commission
Adapted from A junior doctor’s guide to the NHS. NHS medical directorate. 2009. Available at http://group.bmj.com/group/affinity-and-society-publishing/NHS%20Guide.pdf. Accessed October 2013.
Parliament and Secretary of State
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
Challenges facing the NHS today
• An ageing patient population
• Medical advances– What is possible?– What can the NHS afford?– Will investments deliver long-term value?
• Lifestyle factors
• Rising healthcare costs
• Rising patient expectations around the quality of patient care
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
Do guidelines keep pace with therapeutic advances?
1920s
Insulin1
1930s
Long acting insulin1
Sulphonylureas4
1960s 1970s
HbA1c
1990s
Metformin4
Human insulin analogue1
T1D: Type 1 diabetes. T2D: Type 2 diabetes. The examples of approved glucose lowering agents is not exhaustive.All online resources accessed October 2013.1. Adapted from History of Diabetes in Timeline. Defeat Diabetes Foundation. Available at http://www.defeatdiabetes.org/about_diabetes/text.asp?id=Diabetes_Timeline. 2. Guidelines from National Institute for Health and Clinical Excellence. Available at http://www.nice.org.uk.3. SmPCs available from http://www.medicines.org.uk/EMC/default.aspx.4. FDA approval for sulphonylureas (tolbutamide as example) and metformin. Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
Acarbose3
2000
Pioglitazone3
2005 2010 2013/2014
Sitagliptin3
Linagliptin3
Saxagliptin3
Vildagliptin3
Exenatide long-acting3
Meglitinides3Liraglutide3
CG87:T2D management2
CG15:T1D management2
CG63:Diabetes in pregnancy2
CG119:Diabetes foot problems2
Lixisenatide3
Dapagliflozin3
Insulin degludec3
Exenatide3
Alogliptin3
Canagliflozin3
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
Biggest shake-up of the NHS to date
• This government white paper was developed after the 2010 elections
• It represents the biggest shake-up of the structure of the NHS to date, summarised as follows:
– ‘The Government will devolve power and responsibility for commissioning services to the healthcare professionals closest to patients: GPs and their practice teams working in consortia’
Equity and excellence: Liberating the NHS. July 2010. © Crown Copyright 2010. Available at http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_117794.pdf. Accessed October 2013.
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
Proposed NHS structure: post-April 2013
Department of Health
NHS commissioning board
Regional office
27 Local offices
212 Clinical commissioning groups
Public Health England
Local council
Health and wellbeing
board
Regional office
Regional office
Regional office Primary care
Hospital care
Community care
Mental health
Monitor
Adapted from The structure of the NHS in England. NHS Choices. Available at : http://www.nhs.uk/NHSEngland/thenhs/about/Pages/nhsstructure.aspx. Accessed October 2013.
Parliament and Secretary of State
Specialist/ tertiary care
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
Treatment purchasing and planning
Primary care trust
GPs
NHS hospital
Private hospital
Community
care
Private/charity
community care
GP-led clinical commissioning groups (>200)
NHS hospital
Private hospital
Community care
Private/charity
community care
Private consultancy
Commissioning support group
Pre-April 20131,2 From April 20133,4
All online resources accessed October 2013.1. Delivering primary care. Department of Health (archived content) 2010. Available at http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Aboutus/HowDHworks/DH_074639.2. NHS funding and expenditure. House of Commons Library. 2011. Available at http://www.nhshistory.net/parlymoney.pdf. 3. Adapted from the Health and Social Care Act. 2012. Overview of health and care structures. Available at http://www.dh.gov.uk/health/files/2012/06/A3.-Factsheet-Overview-of-health-
and-care-structures-240412.pdf.4. Adapted from “Commissioning developments: key facts. Available at http://www.commissioningboard.nhs.uk/files/2013/01/com-dev-facts.pdf.
GPsNon-profit
bodies
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
Control of funding
Pre-April 20131,2 From April 20133,4
Primary care trust
GPs GPs GPs GPs GPs
GPs GPs GPs
GPs GPs GPs
Clinical commissioning groups
All online resources accessed October 2013.1. Delivering primary care. Department of Health (archived content) 2010. Available at http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Aboutus/HowDHworks/
DH_074639.2. NHS funding and expenditure. House of Commons Library. 2011. Available at http://www.nhshistory.net/parlymoney.pdf. 3. Adapted from the Health and Social Care Act. 2012. Overview of health and care structures. Available at http://www.dh.gov.uk/health/files/2012/06/A3.-Factsheet-Overview-of-
health-and-care-structures-240412.pdf. 4. Adapted from ‘Who pays? Determining responsibility for payment to providers.”’ Rules and guidance for clinical commissioning groups. Available at
http://www.commissioningboard.nhs.uk/files/2012/12/who-pays.pdf.
NHS hospital
Private hospital
Community
care
Private/charity
community care
GPs NHS hospital
Private hospital
Community care
Private/charity
community care
Non-profit
bodies
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
NHS Reform – from April 2013• Wider range of health care
providers
• Clinical commissioning groups (CCGs) of HCPs, which will commission services
• Local healthwatch will give patients/communities a voice in decisions that affect them
• Complex web of care?
Available at: http://healthandcare.dh.gov.uk. Crown copyright © 2011 licensed under the Open Government licence v1.0. Accessed October 2013.
HCPs: healthcare professionals.
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
Diabetes and the state of care: The need for improvement• In 2010/11 dealing with diabetes cost the NHS £9.8 billion, 10% of the NHS
budget1
– 80% of this was spent on dealing with diabetic complications including blindness and amputations2
• Approximately half of people with T2D and two thirds of people with T1D fail to receive all nine clinically recommended annual tests and investigations2
• Variations in standards of care demonstrate the need for organised, co-ordinated and structured models of integrated care delivery2
• People with diabetes need clear consistent information about:– Which services they need to go to2
– Frequency of monitoring2
1. Hex N, et al. Diabetic Medicine. 2012; 29:855–862.2. Protecting and promoting patients’ interests – licensing providers of NHS services. Diabetes UK response to the consultation. 2012. Available at
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/156471/Diabetes-UK-revised.pdf.pdf . Accessed October 2013.
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
Diabetes care cannot be delivered by one provider alone• Development of effective integrated services requires input from a
range of provider teams
• Primary care, community services, specialist teams and tertiary services, alongside people with diabetes, need to work together to advise on– Local pathways– Commissioning– Co-ordination between providers through effective local diabetes
networks
• “Local primary, community, voluntary and private providers can’t do it on their own and they shouldn’t think they can” – Diabetes UK
Protecting and promoting patients’ interests – licensing providers of NHS services. Diabetes UK response to the consultation. 2012. Available at https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/156471/Diabetes-UK-revised.pdf.pdf. Accessed October 2013.
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
Enhancing quality of life for people with long-term conditions• The 2012 NHS mandate set out measures that are essential to
– Support people living with long-term conditions– Improve the care they receive– Improve their quality of life
• By 2015 it is hoped that:– ‘Far more people will have developed the knowledge, skills and
confidence to manage their own health, so they can live their lives to the full’
• Education for patients and their carers will be essential to provide the necessary skills and information to manage and monitor their medical conditions
Adapted from The mandate. A mandate from the Government to the NHS Commissioning Board: April 2013 to March 2015. November 2012. Available at https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/127193/mandate.pdf.pdf. Accessed October 2013.
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
• Diabetes Education and Self Management for Ongoing and Newly Diagnosed1
• Structured education programme of choice for over 110 healthcare organisations across Great Britain and Ireland, for people with T2D
• Cost-utility analysis2
• Incremental cost of DESMOND = £82• Mean incremental cost/QALY
gained = £2092• Beneficial and cost effective?
• ‘Family’ of patient education modules and related Educator training:1
• Newly Diagnosed• Foundation- (for those who have
established diabetes) • BME- course delivered in Gujarati,
Punjabi, Urdu and Bengali• Walking Away from Diabetes (for those
at high risk of developing Type 2 diabetes)
1. Available at: http://www.desmond-project.org.uk/. Accessed October 2013. Image copyright granted by the DESMOND© team.2. Gillet M, et al. BMJ. 2010; 341:c4093.
Structured education to provide self-management skills – DESMOND
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
NSF/NICE guidance: Key care processes for diabetes
• Blood glucose level measurement
• BP measurement
• Cholesterol level measurement
• Retinal screening
• Foot and leg check
• Kidney function testing (urine)
• Kidney function testing (blood)
• Weight check
• Smoking status check
NSF: National Service Framework 2001. NICE: National Institute for Health and Clinical Excellence; BP: blood pressure.
Diabetes UK. State of the Nation 2012. England. Available at http://www.diabetes.org.uk/Documents/Reports/State-of-the-Nation-2012.pdf. Accessed October 2013.
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
The Outcomes Framework identifies the current NHS quality improvement system
Department of Health. The NHS Outcomes Framework 2011/12. December 2011. Crown copyright © 2010 licensed under the Open Government licence v1.0. Available at:
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/135554/dh_123138.pdf.pdf. Last accessed October 2013.
Duty of quality
Duty of quality
Du
ty o
f q
ua
lity D
uty o
f qu
ality
Domain 1Preventing people
from dying prematurely
Domain 2Enhancing quality of life for people with
long-term conditions
Domain 3Helping people to
recover from episodes of ill health or following
injury
Domain 4Ensuring that people
have a positive experience of care
Domain 5Treating and caring for
people in a safe environment and
protecting them from avoidable harm
NHS Outcomes Framework
NICE Quality Standards(Building a library of approx 150 over 5 years)
Commissioning OutcomesFramework
Commissioning Guidance
Provider payment mechanisms
tariffStandard contract
CQUIN QOF
Commissioning / ContractingNHS Commissioning Board – certain specialist services and primary care GP consortia – all other health care services
71
2
3 4 5
6
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
NICE Quality Standards 6: Diabetes in adults
QS6
Structured educationNutrition and
physical activity advice
Care planning
Glycaemic control
Medication
Insulin therapy
Preconception care
Complications
Psychological care
‘At risk’ foot
Foot problems needed urgent
medical attention
Inpatient care
Diabetic ketoacidosis
Hypoglycaemia
QS6: Quality Standard 6.Diabetes in adults quality standard. National Institute for Health and Clinical Excellence. 2011. Available at http://publications.nice.org.uk/diabetes-in-adults-quality-standard-qs6. Accessed October 2013.
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
Diabetes Outcome Versus Expenditure tool
• Diabetes care expenditure vs clinical outcomes for – A selected CCG– Other CCGs with similar populations– All other CCGs
1. Diabetes Outcomes Versus Expenditure Tool (DOVE). Yorkshire and Humberside Public Health Observatory. Available at http://www.yhpho.org.uk/. Accessed October 2013 Contains public sector information licensed under the Open Government Licence v1.0 available at http://www.nationalarchives.gov.uk/doc/open-government-licence/. Accessed October 2013.
CCGs: Clinical Commissioning Groups.
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
Clinical Commissioning Group (CCG) Outcomes Indicator Set (CCGOIS) (2012/2013)
• Formerly known as the Commissioning Outcomes Framework (COF)1
• Measuring outcomes of services commissioned by CCGs1
• Indicators do not relate to commissioning itself
• Outcomes indicators have been derived directly from the NHS Outcomes Framework, based on NICE Quality Standards, or from existing data1
Diabetes indicators2
Myocardial infarction, stroke and stage 5 chronic kidney disease
Patients who have received nine care processes
Newly diagnosed patients (<1 year) who are referred to structured education
Patients who have emergency admission for diabetic ketoacidosis
Complications associated with diabetes
Lower limb amputation in diabetes patients
1. About the Clinical Commissioning Group Outcomes Indicator Set (CCGOIS). National Institute for Health and Clinical Excellence. Available at: http://www.nice.org.uk/aboutnice/cof/cof.jsp. Last updated January 2013. Accessed October 2013.
2. Endocrine, nutritional and metabolic indicators. National Institute for Health and Clinical Excellence. Available at: http://www.nice.org.uk/aboutnice/cof/EndocrineNutritionalAndMetabolic.jsp. Last updated September 2012. Accessed October 2013.
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
Quality and Outcomes Framework for diabetes 2013/2014• Introduced in 2004 as part of the GMSC with annual publication of
practice scores1
Payment for GP
practices
SEPARATE INDICATORS• Blood pressure• Testing foot sensation• Foot examination and risk
classification• HbA1c control• Structured education referral• Dietary review• Records of confirmed diabetes
diagnosis• Erectile dysfunction consultations,
assessment and treatment options• Proteinuria screening
Points
2013/14 menu of indicators2
1. About the Quality and Outcomes Framework (QOF). National Institute for Health and Clinical Excellence. Available at: http://www.nice.org.uk/aboutnice/qof/qof.jsp. Last updated August 2013. Accessed October 2013.
2. NICE menu of indicators. Endocrine nutritional and metabolic. Available at: http://www.nice.org.uk/aboutnice/qof/indicators.jsp. Last updated August 2013. Accessed October 2013..
2012–13: 88 QOF points2013–14: 106 QOF points
QOF: Quality and Outcomes Framework; GMSC: General Medical Services Contract.
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
A composite QOF indicator for diabetes?
• Joint DoH/NICE initiative to boost routine assessment of patients with diabetes
• National Diabetes Audit (2011) results suggested only half of patients with diabetes received all nine checks
CurrentNine INDIVIDUAL
checks
For 2015 QOF?Bundle individual checks into a SINGLE indicator
Pulse. Revealed: DH plans to bundle diabetes QOF indicators worth over £5000. July 2012. Available at http://www.pulsetoday.co.uk/revealed-dh-plans-to-bundle-diabetes-qof-indicators-worth-over-5000/14224104.article. Accessed October 2013.
Payment for GP
practices
QOF: Quality and Outcomes Framework; DoH: Department of Health.
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
Implications of the impact of the NHS changes on diabetes care?
Increased GP practice workload
Practice income
Management of complex clinical processes
Performance vs financial reward
Patient-prescriber relationship
Additional practice training needs
Standard of care
QOF monitoring requirements vs patient uptake
Measurement of the integrated care pathway
Competition
QOF: Quality and Outcomes Framework.
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
Summary and learning points
• Re-structuring of the NHS framework could be one of the most radical and far-reaching reviews in its history
• Potential mid- and long-term implications of these changes include:– Altered patient access to the complex network of diabetes care services – A review of the type and frequency of vital health checks received by
patients– Additional responsibilities for provision of primary care services– A review of/changes to patient-oriented outcomes
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
Prescribing information
This presentation has been developed by Boehringer Ingelheim Ltd. and Eli Lilly Company Ltd. UK/TRJ/00296a(1). April 2014.
Prescribing information